Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study confirmed the localization of CK19 and vimentin in skin cells, with CK19 linked to hair growth and vimentin stabilizing fibroblast structure.

In this case report, the researchers documented a rare instance of plica neuropathica, characterized by matted and twisted hair, occurring alongside diffuse alopecia, marking the first such documented association and emphasizing its diagnostic challenges in identifying causes of alopecia.

This study found that topical minoxidil can be effective in preventing flap necrosis during latissimus dorsi flap reconstruction in patients who have undergone neoadjuvant chemoradiation.

In this study, topical application of 5% minoxidil significantly increased hair follicle density in a mouse model of androgenetic alopecia, as evidenced by a rise in density from 24.00 in the control group to 40.14 in the treatment group.

This study focused on developing a nanoemulsion-based gel for delivering minoxidil, aiming to enhance its contact time with the scalp and potentially improve skin absorption compared to conventional topical solutions.

In this animal study, topical minoxidil shortened the telogen phase of hair growth cycles in rats, suggesting it may stimulate certain follicles to progress more rapidly to anagen.

This study reported that while topical minoxidil exhibits hair regrowth in androgenetic alopecia, oral minoxidil 5 mg/day was more effective than topical forms after six months, with low doses also potentially effective for women and other hair loss types.

In this study, the addition of a SULT1A1 enzyme booster to daily 5% minoxidil treatment significantly increased hair regrowth in men with androgenic alopecia compared to minoxidil alone.

This study found that platelet-rich plasma therapy led to greater improvements in hair density and patient satisfaction compared to topical 5% Minoxidil in androgenetic alopecia patients over 12 weeks.

This integrative review found that triamcinolone hexacetonide remains the primary treatment for mild to moderate alopecia areata but noted its significant side effects with prolonged use, while emerging therapies like PRP and minoxidil offer promising alternative benefits with fewer risks.

This study found that while the over-the-counter market for minoxidil hair loss products is expanding, only 25% of these products report safety information, and none report adverse effects, highlighting a need for greater transparency and accuracy in their advertising.

This study compared the clinical effectiveness of platelet-rich plasma therapy with minoxidil for treating hair loss in men, suggesting PRP is a promising option.

In this study, intradermal injections of 0.5% minoxidil significantly improved hair growth and volume in women with female androgenetic alopecia compared to a placebo, with a good safety profile reported.

In this observational study, the combination of PRP and 5% minoxidil was more effective than minoxidil alone in promoting hair growth in men with androgenetic alopecia.

Results are not reported in this abstract, which focuses on promoting the offerings of a medical publisher in Delhi, India, including open access and print journals across various medical disciplines.

This study observed that both intradermotherapy with 5% minoxidil and topical minoxidil application resulted in perceived improvements in hair density and thickness among patients with androgenetic alopecia, with no significant difference between the two groups.

This study found that minoxidil pretreatment in rat skin flaps enhanced angiogenesis and increased flap survival compared to untreated flaps, but was less effective at reducing necrosis than surgical delay.

This study found that a once-daily 5% minoxidil topical foam is as effective as a twice-daily 2% minoxidil topical solution for hair growth in women with androgenetic alopecia, with fewer side effects and greater styling convenience.

This study concluded that a combined once-daily solution of 5% minoxidil and 0.01% tretinoin is as effective and safe as the conventional twice-daily 5% minoxidil application for treating androgenetic alopecia in men.

This study found that different species metabolized minoxidil into various products, with monkeys and humans showing similar profiles primarily excreting a glucuronide conjugate, while rats and dogs showed distinct differences.

This study found that combining microneedle treatments with 5% minoxidil topical solution led to the greatest increase in hair density among Chinese men with androgenetic alopecia.

This study found that combining fractional radiofrequency microneedling with 5% topical minoxidil improved hair count and thickness more than minoxidil alone in Chinese men with male pattern hair loss.

This article reviews the proposed mechanism of minoxidil in treating androgenetic alopecia, suggesting it may prolong the anagen phase by modulating cell growth factors and vascular activity, but reports no new results.

Minoxidil effectively treats hair loss, works better for women, and requires consistent use.

This review discusses the potential of nanotechnology-based formulations for delivering topical minoxidil to improve hair loss treatment outcomes and reports no new clinical results, urging further research into their benefits and safety considerations.

This research investigated aqueous alginate-based hydrogels for delivering minoxidil and reported that using hydroxypropyl-β-cyclodextrin (HP-β-CD) with molar substitution 0.65 significantly enhanced minoxidil's solubility and skin permeability without damaging the epidermis, suggesting potential as an alternative to commercial minoxidil solutions.

This study found that the MXD/HP-β-CD GEL formulation promoted greater hair growth and improved gene expression related to hair growth in male rats compared to MXD solution or control groups.

This review discusses the emerging pathophysiological factors and potential new therapies for androgenetic alopecia beyond traditional treatments, but reports no new results.

This article has no abstract and reports no new findings, focusing instead on allergic contact dermatitis reactions to topical Minoxidil documented in previous studies.

This study suggests that analyzing hair care product components left on hair using GC and GC-MS may provide a more objective forensic comparison than morphological examination.